OncoSec Medical Inc (ONCSQ)

[$Moneypenny$]

Jean Campbell is such a great hire for so many reasons. However, what struck me the most was that she is not an oncologist by an assistant professor/biochemist who runs a research lab. What was triggered in my mind was the BioCeo conference where one of the slides listed the broad applicability of ImmunoPulse that is BEYOND cancer to include all kinds of diseases where the delivery system of ImmunoPulse lowers toxicity and costs in other infectious diseases. Punit even mentioned this as a possible long term possibilities for ImmunoPulse. I believe (and I hope) we are seeing the first sign that ONCS is planning to go beyond cancer. I'm really curious what the rest of you think.

For example, they list three areas where they list the broad application in their Corporate presentation listed on their website (Descriptions are from Wikipedia). The basic jist is that there is a whole array of diseases that ImmunoPulse could help:

1. Proinflammatory Cytokine: a cytokine which promotes systemic inflammation. Due to their proinflammatory action, they tend to make a disease worse by producing fever, inflammation, tissue destruction, and, in some cases, even shock and death. Reducing the biological activities of proinflammatory cytokines can reduce the brunt of attack of diseases mediated by proinflammatory cytokines. Blocking IL-1 or TNF has been highly successful in patients with rheumatoid arthritis, inflammatory bowel disease, or graft-vs-host disease.

2. Immuno-modulator receptors: I can't quite figure this one out. If anyone can, please help.

3. Cell trafficking molecules: I can't quite figure this one out either. If anyone can, please help.


Attached is the link to the conference:

http://www.veracast.com/bio/ceoinvestor2014/main/events/1404_oncose/pdf/OncoSec_Medical.pdf


Below is a link to Jean Campbell's profile at University of Washington:

http://www.pathology.washington.edu/faculty/campbell